scholarly journals Progression marker of Parkinson’s disease: a 4-year multi-site imaging study

Brain ◽  
2017 ◽  
Vol 140 (8) ◽  
pp. 2183-2192 ◽  
Author(s):  
Roxana G Burciu ◽  
Edward Ofori ◽  
Derek B Archer ◽  
Samuel S Wu ◽  
Ofer Pasternak ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Imaging Study ◽  
Progression Marker

Normal Cognition in Parkinson’s Disease may Involve Hippocampal Cholinergic Compensation: a PET Imaging Study with [18F]-FEOBV

2021 ◽  
Author(s):  
Camille Legault-Denis ◽  
Meghmik Aghourian ◽  
Jean-Paul Soucy ◽  
Pedro Rosa-Neto ◽  
Alain Dagher ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Pet Imaging ◽  
Imaging Study ◽  
Normal Cognition

scholarly journals Re-emergent tremor in patients with Parkinson’s disease: an imaging study

2020 ◽  
Vol 3 (2) ◽  
pp. 106
Author(s):  
PramodK Pal ◽  
Pooja Mailankody ◽  
Lija George ◽  
RajiniM Naduthota ◽  
Jitender Saini ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Imaging Study

scholarly journals Parkinson’s disease prognostic scores for progression of cognitive decline

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Galina Gramotnev ◽  
Dmitri K. Gramotnev ◽  
Alexandra Gramotnev
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Decline ◽  
Clinical Problem ◽  
Prognostic Scores ◽  
Clinical Biomarkers ◽  
Clinical Scores ◽  
Progression Marker ◽  
Drug Naïve ◽  
Relative Variable

AbstractClinical and biochemical diversity of Parkinson’s disease (PD) presents a major challenge for accurate diagnosis and prediction of its progression. We propose, develop and optimize PD clinical scores as efficient integrated progression biomarkers for prediction of the likely rate of cognitive decline in PD patients. We considered 269 drug-naïve participants from the Parkinson’s Progression Marker Initiative database, diagnosed with idiopathic PD and observed between 4 and 6 years. Nineteen baseline clinical and pathological measures were systematically considered. Relative variable importance and logistic regressions were used to optimize combinations of significant baseline measures as integrated biomarkers. Parkinson’s disease cognitive decline scores were designed as new clinical biomarkers using optimally categorized baseline measures. Specificities and sensitivities of the biomarkers reached ~93% for prediction of severe rate of cognitive decline (with more than 5 points decline in 4 years on the Montreal Cognitive Assessment scale), and up to ~73% for mild-to-moderate decline (between 1 and 5 points decline). The developed biomarkers and clinical scores could resolve the long-standing clinical problem about reliable prediction of PD progression into cognitive deterioration. The outcomes also provide insights into the contributions of individual clinical and pathological measures to PD progression, and will assist with better-targeted treatment regiments, stratification of clinical trial and their evaluation.

scholarly journals PET Imaging of the Adenosine A2A Receptor in the Rotenone-Based Mouse Model of Parkinson’s Disease with [18F]FESCH Synthesized by a Simplified Two-Step One-Pot Radiolabeling Strategy

Molecules ◽  
2020 ◽  
Vol 25 (7) ◽  
pp. 1633
Author(s):  
Susann Schröder ◽  
Thu Hang Lai ◽  
Magali Toussaint ◽  
Mathias Kranz ◽  
Alexandra Chovsepian ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Small Animal ◽  
Imaging Study ◽  
Adenosine A2a Receptor ◽  
Emission Tomography ◽  
One Pot ◽  
Positron Emission ◽  
A2a Receptor ◽  
Adenosine A2a

The adenosine A2A receptor (A2AR) is regarded as a particularly appropriate target for non-dopaminergic treatment of Parkinson’s disease (PD). An increased A2AR availability has been found in the human striatum at early stages of PD and in patients with PD and dyskinesias. The aim of this small animal positron emission tomography/magnetic resonance (PET/MR) imaging study was to investigate whether rotenone-treated mice reflect the aspect of striatal A2AR upregulation in PD. For that purpose, we selected the known A2AR-specific radiotracer [18F]FESCH and developed a simplified two-step one-pot radiosynthesis. PET images showed a high uptake of [18F]FESCH in the mouse striatum. Concomitantly, metabolism studies with [18F]FESCH revealed the presence of a brain-penetrant radiometabolite. In rotenone-treated mice, a slightly higher striatal A2AR binding of [18F]FESCH was found. Nonetheless, the correlation between the increased A2AR levels within the proposed PD animal model remains to be further investigated.

Structural and functional imaging study in dementia with Lewy bodies and Parkinson's disease dementia

2015 ◽  
Vol 21 (9) ◽  
pp. 1049-1055 ◽  
Author(s):  
Barbara Borroni ◽  
Enrico Premi ◽  
Anna Formenti ◽  
Rosanna Turrone ◽  
Antonella Alberici ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Functional Imaging ◽  
Dementia With Lewy Bodies ◽  
Lewy Bodies ◽  
Imaging Study ◽  
Parkinson’S Disease Dementia ◽  
Functional Imaging Study
Sign in / Sign up

Export Citation Format

Share Document